Abstract
Human serum paraoxonase 1 (PON1), a high-density lipoprotein (HDL)-associated enzyme, has been shown to reduce the oxidation of low-density lipoprotein (LDL) and HDL by degrading lipid peroxides. This property of PON1 accounts for its ability to protect against atherosclerosis. In this study, we identified four polymorphisms in both the coding (L55M and Q192R) and regulatory regions (T-108C and G-909C) of the human PON1 gene in 202 healthy Thai individuals and investigated the influence of these polymorphisms on serum PON1 activity towards three substrates, namely, paraoxon, phenylacetate and diazoxon. The PON1 L55M, Q192R and G-909C polymorphisms significantly affected the variation in serum PON1 activity towards paraoxon. Serum PON1 activity towards paraoxon was significantly different among the genotype groups, as follows: 55LL > 55LM/55MM, 192RR > 192QR > 192QQ and −909CC > −909CG > −909GG. The PON1 Q192R and G-909C polymorphisms also influenced the variation in serum PON1 activity towards diazoxon but in the opposite direction to the activity towards paraoxon. Only the PON1 L55M polymorphism was associated with significant variation in serum PON1 activity towards phenylacetate while the PON1 T-108C polymorphism had no significant effect on serum PON1 activity towards any substrate. We also found linkage disequilibrium among the polymorphic sites, including Q192R versus L55M, Q192R versus T-108C and Q192R versus G-909C. Serum PON1 activity towards both paraoxon and phenylacetate, but not diazoxon, was positively correlated with HDL cholesterol (HDL-C) and apo AI concentrations. None of the PON1 polymorphisms significantly affected serum lipid, lipoprotein or apolipoprotein concentrations. Our findings suggest that the physiological relevance of the PON1 polymorphisms is that they are associated with significant differences in serum PON1 activity, and the impact of PON1 polymorphisms on this activity is substrate-dependent.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812–1818
Adkin S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598–608
Aviram M (1999) Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 5:381–386
Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du BN (1998a) Paraoxonase active site required for protection against LDL oxidation involves its free sulhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18:1617–1624
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998b) Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101:1581–1590
Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000) Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. PON1 esterase and peroxidase-like activities. Circulation 101:2510–2517
Balogh Z, Fulop P, Seres I, Harangi M, Katona E, Kovacs P, Kosztaczky B, Paragh G (2001) Effect of simvastatin on serum paraoxonase activity. Clin Drug Invest 21:505–510
Blatter MC, James RW, Messmer S, Barja F, Pometta D (1993) Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein K-45. Eur J Biochem 211:871–879
Blatter MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu 54 is associated with modified concentrations of the enzyme. J Clin Invest 99:62–66
Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE (2000) Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 10:453–460
Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001) Effects of 5′ regulatory region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428–1436
Cao H, Girard-Cloba A, Serusclat A, Bernard S, Bondon P, Piicard S, Berthezene F, Moulin P (1998) Lack of association between carotid intima-media thickness and paraoxonase polymorphisms in non-insulin dependent diabetes mellitus. Atherosclerosis 138:361–366
Cao H, Girard-Globa A, Berthezene F, Moulin P (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 40:133–139
Datoine TF, Debord J, Charmes JP (1998) Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9:2082–2088
Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334–336
Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35:197–203
Ferretti G, Bacchetti T, Maratti E, Curatola G (2003) Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity. Metabolism 52:146–151
Hegele RA, Brunt JH, Connelly PW (1995) A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 15:89–95
Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, Bard JM, Cambien F (1996) The Gln/Arg polymorphism of human paraoxonase (PON192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 126:299–303
Humbert R, Alder DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73–76
Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin dependent diabetes mellitus. Metabolism 47:598–602
Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435–442
Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 20:2441–2447
Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516–521
Leviev I, Negro F, James RW (1997) Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met 54) polymorphism. Arterioscler Thomb Vasc Biol 17:2935–2939
Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE (2000) Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767–779
Mackness MI, Arrol S, Durrington PN (1991a) Paraoxonase prevents accumulation of lipidperoxide in low-density lipoprotein. FEBS Lett 286:152–154
Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M (1991b) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86:193–199
Mackness MI, Arrol S, Abbott CA, Durrington PN (1993) Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104:129–135
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1997a) Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122:265–268
Mackness MI, Arrol S, Mackness B, Durrington PN (1997b) Alloenzymes of paraoxonase and effectiveness of high-density lipoprotein in protecting low-density lipoprotein against lipid peroxidation. Lancet 349:851–852
Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN (1998a) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341–349
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998b) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Lett 423:57–60
Mackness B, Durrington PN, McElduff P, Yarnell J, Azam N, Watt M, Mackness MI (2003) Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107:2775–2779
Odawara M, Tachi Y, Yamashita K (1997) Paraoxonase polymorphism (Gln192Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257–2260
Ombres D, Pannitteri G, Montali A, Gandeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M (1998) The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18:1611–1616
Paragh G, Seres I, Balogh Z (1998) The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80:166–170
Paragh G, Balagh Z, Seres I, Harangi M, Boda J, Kovacs P (2000) Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin Drug Invest 19:277–282
Richter RJ, Furlong CE (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745–753
Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochemistry J 354:1–7
Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS (1991) Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins. Clin Genet 40:277–282
Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067–1073
Sanghera DK, Saha N, Kamboh MI (1998) The codon 55 polymorphism in the paraoxonase1 gene is not associated with the risk of coronary heart disease in Asian Indian and Chinese. Atherosclerosis 136:217–223
Serrato M, Marian AJ (1995) A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005–3008
Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, Tanaka H, Hashimoto K (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295–298
Sutherland WHF, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL (1999) Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thomb Vasc Biol 19:1340–1347
Tomas M, Senti M, Elosua R, Vila J, Sala J, Masia R, Marrugat J (2001) Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol 432:121–128
Tomas M, Elosua R, Senti M, Molina L, Vila J, Anglada R, Fito M, Covas MI, Marrugat J (2002) Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity. J Lipid Res 43:713–720
Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, Hui R, Yao Z, Shen Y, Qiang B, Gu D (2003) Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 23:328–334
Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM (1995) Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest 96:2882–2891
Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363:689–695
Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y (1997) A 192 Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565–3569
Acknowledgements
We would like to thank Gp. Capt. Surasak Prongchantuk, the director of the Division of Preventive Medicine, Royal Thai Air Force, for allowing us to collect blood samples. We are grateful to Dr. Preecha Chaloeiphap for his assistance in blood collection. We wish to thank Maria Mastorikou, Mathew Wright and Yifen Liu for skillful assistance. This study was supported by a grant from the Ministry of University Affairs, Thailand.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Phuntuwate, W., Suthisisang, C., Koanantakul, B. et al. Paraoxonase 1 status in the Thai population. J Hum Genet 50, 293–300 (2005). https://doi.org/10.1007/s10038-005-0255-7
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-005-0255-7
Keywords
This article is cited by
-
Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution
Lipids in Health and Disease (2016)
-
Paraoxonase 1 Polymorphisms Within a Mississippi USA Population as Possible Biomarkers of Enzyme Activities Associated With Disease Susceptibility
Biochemical Genetics (2014)
-
Reply to: "Paraoxonase-1 and clopidogrel efficacy"
Nature Medicine (2011)
-
Biochemical, Environmental, and Genetic Factors Associated with Paraoxonase (PON1) Activity
Biochemical Genetics (2011)
